Gabrielle J. Knafler

Fairfield University — United States

Chemistry · Physical Sciences

6h-index222citations34works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Click Chemistry and Applications(21), Histone Deacetylase Inhibitors Research(13), Cancer-related gene regulation(12), Genetic diversity and population structure(4), Genetic and phenotypic traits in livestock(3)

Publications34 total

Figure 5 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S8 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Data from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure 6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Table S2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Table S1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S9 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Table 1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure 3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure 2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Table S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure 7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S10 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
Figure S6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025Open Access
page 1 of 2Next →

Frequent Co-authors

Christopher D. Collier(25), Patrick J. Getty(25), Edward M. Greenfield(25), James D. Buschbach(24), Emily E. Seiden(23), Spencer M. Richardson(23), Alyssa L. Walker(23), Venetia A. Whiteside(23), Deep A. Gandhi(23), M. Reza Saadatzadeh(23), Sheldon L. Padgett(23), Rance M. Gamblin(23), Michael O. Childress(23), Christopher M. Fulkerson(23), Karen E. Pollok(23), Leah A. Everitt(22), Divya Pillutla(22), Shrey Ramnath(22), Gavin P. Kinsella(22), Piper A. Wilburn(22)